Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression
NeoAg architectures modulate the immunogenicity of NeoAg and tumors by dictating the interplay between concurrent T-cell responses mediated by cDC1. Impaired induction of T-cell responses supports immune evasion in tumors with heterogenous NeoAg expression but is amenable to NeoAg architecture-informed vaccination, which in combination with ICB portrays a promising treatment approach for patients with tumors exhibiting high ITH.
Authors
- Malte Roerden (ORCID: https://orcid.org/0000-0001-7283-9778)
- Forest M. White (ORCID: https://orcid.org/0000-0002-1545-1651)
- Yufei Cui (ORCID: https://orcid.org/0000-0003-3014-813X)
- Stefani Spranger (ORCID: https://orcid.org/0000-0003-3257-4546)
- Kevin Litchfield (ORCID: https://orcid.org/0000-0002-3725-0914)
- Jonathan Dye (ORCID: https://orcid.org/0000-0003-2801-8053)
- Laura Maiorino (ORCID: https://orcid.org/0000-0001-8217-1337)
- Andrea Castro (ORCID: https://orcid.org/0000-0002-5873-2496)
- B.J. Kim (ORCID: https://orcid.org/0000-0001-8131-5255)
- Darrell J. Irvine (ORCID: https://orcid.org/0000-0002-8637-1405)
- Noora Harake (ORCID: https://orcid.org/0009-0008-6166-1247)
Institutions
- Howard Hughes Medical Institute (US)
- Cancer Research UK (GB)
- Ragon Institute of MGH, MIT and Harvard (US)
- London Cancer (GB)
- CRUK Lung Cancer Centre of Excellence (GB)
- University College London (GB)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-010249
- Citations
- 16
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- Howard Hughes Medical Institute
- Cancer Research Institute
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Cancer Institute